Currently, the longest OS of EGFR mutant lung cancer patients treated by single agent EGFR-TKI is 38.6 month from the FLAURA study which proved the concept and the clinical benefit of EGFR-TKI as the first-line treatment (11). Here, EGFR is linked to lung carcinoma.